Future applications of FGF/FGFR inhibitors in cancer. Issue 9 (2nd September 2018)

• Record Type: Journal Article
• Authors: Ghedini, Gaia Cristina; Ronca, Roberto; Presta, Marco; Giacomini, Arianna
• Is Part Of: Expert review of anticancer therapy. Volume 18:Issue 9(2018)
• Page Start: 861
• Page End: 872
• Publication Date: 2018-09-02
• Subjects: Fibroblast growth factor -- fibroblast growth factor receptor -- cancer -- tyrosine kinase inhibitors -- monoclonal antibodies -- FGF traps; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2018.1491795
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction : Deregulation of the fibroblast growth factor (FGF)/FGF receptor (FGFR) network occurs frequently in tumors due to gene amplification, activating mutations, and oncogenic fusions. Thus, the development of FGF/FGFR-targeting therapies is the focus of several basic, preclinical, and clinical studies. Areas covered : This review will recapitulate the status of current FGF/FGFR-targeted drugs. Expert commentary : Non-selective FGF/FGFR inhibitors have been approved for cancer treatment but evidence highlights various complications affecting their use in the clinical practice. It appears mandatory to identify FGF/FGFR alterations and appropriate biomarkers that may predict and monitor response to treatment, to establish the contribution of the FGF/FGFR system to the onset of mechanisms of drug resistance, and to develop effective combinations of FGF/FGFR inhibitors with other targeted therapies.